NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00078-0668-15 | 00078-0668 | Trametinib | Mekinist | 2.0 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | March 17, 2016 | April 30, 2024 | In Use |
50242-0090-01 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Aug. 17, 2011 | Feb. 28, 2018 | In Use |
50242-0090-02 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Sept. 8, 2015 | In Use | |
50242-0090-86 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | April 10, 2014 | In Use | |
00078-0666-15 | 00078-0666 | Trametinib | Mekinist | 0.5 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | March 17, 2016 | Oct. 31, 2023 | No Longer Used |
00173-0846-08 | 00173-0846 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | Aug. 31, 2018 | No Longer Used |
00173-0847-08 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | May 31, 2018 | No Longer Used |
00173-0847-61 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | June 10, 2013 | Dec. 11, 2014 | No Longer Used |
00173-0847-65 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Oct. 8, 2014 | May 31, 2018 | No Longer Used |
00078-0681-66 | 00078-0681 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | April 1, 2016 | In Use | |
00078-0682-66 | 00078-0682 | Dabrafenib | Tafinlar | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | April 12, 2016 | In Use | |
00173-0849-13 | 00173-0849 | Trametinib | Mekinist | 0.5 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | June 17, 2013 | Dec. 31, 2016 | No Longer Used |
00173-0858-13 | 00173-0858 | Trametinib | Mekinist | 1.0 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | June 17, 2013 | Oct. 5, 2015 | No Longer Used |
00173-0848-13 | 00173-0848 | Trametinib | Mekinist | 2.0 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | June 17, 2013 | Dec. 31, 2016 | No Longer Used |
00173-0848-65 | 00173-0848 | Trametinib | Mekinist | 2.0 mg/1 | Chemotherapy | MEK Inhibitor | BRAF | Oral | June 17, 2013 | Nov. 30, 2016 | No Longer Used |
50242-0717-01 | 50242-0717 | Cobimetinib | Cotellic | 20.0 mg/1 | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Oral | Nov. 10, 2015 | In Use | |
50242-0717-86 | 50242-0717 | Cobimetinib | Cotellic | 20.0 mg/1 | Chemotherapy | MAPK/MEK Inhibitor | BRAF | Oral | Nov. 10, 2015 | In Use | |
68180-0390-09 | 68180-0390 | IMATINIB | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | July 8, 2019 | In Use | |
68180-0391-06 | 68180-0391 | IMATINIB | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | July 8, 2019 | In Use | |
50268-0426-12 | 50268-0426 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 24, 2017 | In Use | |
67184-0532-01 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 21, 2022 | In Use | |
67184-0532-02 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 21, 2022 | In Use | |
67184-0532-03 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 21, 2022 | In Use | |
67184-0533-01 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 21, 2022 | In Use | |
67184-0533-02 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 21, 2022 | In Use |
Found 10,000 results in 11 milliseconds — Export these results